Voriconazole Suspension
NDC Package 40032-038-60

11-digit billing NDC: 40032003860

Package Information

Voriconazole suspension is voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). This formulation utilizes a suspension delivery system. Marketed by Novel Laboratories, Inc., this product is identified by NDC 40032-038 and is authorized under FDA application ANDA206799.

Identification & Billing

NDC Package Code
40032-038-60
Package Description
1 BOTTLE in 1 CARTON / 75 mL in 1 BOTTLE (40032-038-00)
Product Code
11-Digit Billing Format
40032003860
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Voriconazole
Non-Proprietary Name
Voriconazole
Substance Name
Voriconazole
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Voriconazole is indicated in adults and pediatric patients (2 years of age and older) for the treatment of invasive aspergillosis (IA). In clinical trials, the majority of isolates recovered were Aspergillus fumigatus. There was a small number of cases of culture-proven disease due to species of Aspergillus other than A. fumigatus [see Clinical Studies (14.1, 14.5) and Microbiology (12.4)].

Regulatory & Marketing

Labeler Name
Novel Laboratories, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA206799
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-01-2016
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 40032-038-60 identifies a specific commercial package of 1 bottle in 1 carton / 75 ml in 1 bottle (40032-038-00) of Voriconazole, a human prescription drug labeled by Novel Laboratories, Inc.. This suspension is formulated for oral use and contains voriconazole as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novel Laboratories, Inc. on June 01, 2016. The current certification is valid through December 31, 2027.

How is this Novel Laboratories, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 40032003860. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
40032-038-60
11-Digit CMS (5-4-2)
40032-0038-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.